Home
Live Updates
Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML : comparemela.com
Uproleselan Plus Chemotherapy Misses Phase 3 Trial OS End Point in R/R AML
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
Related Keywords
China ,
United States ,
Chinese ,
Harout Semerjian ,
Chinese National Medical Products Administration ,
National Cancer Institute ,
Alliance For Clinical Trials In Oncology ,
Clinical Trials ,
Hematologic Oncology ,
News ,
Acute Myeloid Leukemia ,
Uprolesan ,
comparemela.com © 2020. All Rights Reserved.